Loading...

Member Profile

Home / Members

Taiwan Bio Therapeutics Co., Ltd.




Chairman
  • Chi-Yuan Huang
Date Established
  • 2014/07/25
TWSE Stock ID
  • 6892
Market Valuation
  • USD  60,900,000.0
Phone Number
  • +886-3-668-4788
Address
  • 4F., No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County 302041, Taiwan (R.O.C.)
Website Theraputic Fields
  • Cardiology/Vascular Diseases
  • Endocrinology/Metabolic Disorders
  • Immunology
  • Nephrology
  • Neuroscience
  • Knee Osteoarthritis
Product Classification
  • Regenerative Medicine
  • Technology Platform
Awards
  1. 2015 Taipei Biotech Awards-Technology Transfer Special Mention Award
  2. 2015 Innovation of the Year Award to the Biothech Industry

Taiwan Bio Therapeutics is a regenerative medicine company focused on developing cell therapies as drug products. To date, two candidates in its pipeline have entered Phase IIb clinical trials (Chondrochymal for knee osteoarthritis and Biochymal for wound healing in patients with critical limb ischemia). With its PIC/S GMP-compliant Cell Processing Center, Taiwan Bio also offers contract development and manufacturing (CDMO/CMO) services as well as customized assay development and testing services for cell products.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2014 The business license was acquired, and the actual receipt capital was NT$48,000,000.
   2014 The contact of mesenchymal stem cells technology was signed and transferred from the Taipei Veterans General Hospital and National Yang-Ming University.
   2014 The phase 1/2a clinical trial for the critical limb ischemia was started.
   2015 Subsidized the Angel Project Fund by the National Development Fund.
   2015 Obtained Biotech Innovation of the Year Award from the BioTaiwan 2015.
   2015 Obtain 2015 Technology Transfer Cooperation Award.
   2015 Obtain the subsidy of R&D Organization Technology Development Program from the Ministry of Economic Affairs.
   2016 The patent of preparation of cell transplant in China was gained, which cooperated with the Taipei Veterans General Hospital.
   2016 Become a qualified biotechnology therapeutics company by the Industrial Development Bureau.
   2017 The phase 1/2a clinical trial for the Osteoarthritis was started.
   2017 The phase 1/2a clinical trial for the lower limb ischemia patients enrollment and data analysis was completed.
   2019 The clinical study report of the phase 1/2a clinical trial for the lower limb ischemia patients was approved by Ministry of Health and Welfare.
   2019 The phase 1/2a clinical trial for the osteoarthritis patient enrollment was completed.
   2020 The CSR of phase 1/2a clinical trial for the osteoarthritis was submitted to TFDA.
   2020 A phase I/IIa clinical study of treatment for knee osteoarthritis by intra-articular injection of allogeneic bone marrow derived mesenchymal stem cells was approved by TFDA.
   2020 Purchased a cell preparation center for cell therapy at a price of NT$150 million
   2021 A phase IIb clinical study of treatment for knee osteoarthritis by intra-articular injection of allogeneic bone marrow derived mesenchymal stem cells was approved by TFDA.
   2021 Licensed the CMC of the BMMSC cell bank and phase I IND of AMI treatment by BMMSC technology from ITRI
   2022 A phase IIb clinical trial for the lower limb ischemia patients was approved by TFDA
   2022 Registered on pioneer stock board